PubRank

Z M Younossi

Author PubWeight™ 62.18‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999 11.76
2 Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011 7.91
3 Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001 2.56
4 Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2007 2.31
5 Mushroom poisoning--from diarrhea to liver transplantation. Am J Gastroenterol 2001 1.93
6 Hepatitis C, interferon alfa, and depression. Hepatology 2000 1.91
7 Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther 2012 1.69
8 Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001 1.65
9 An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000 1.42
10 Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010 1.31
11 Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2007 1.17
12 Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000 1.14
13 Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011 1.12
14 Editorial: probiotics in NASH - more studies are needed. Aliment Pharmacol Ther 2014 1.08
15 Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011 1.07
16 Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011 1.07
17 Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001 1.05
18 Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001 1.05
19 Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat 2011 1.01
20 Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 2009 0.97
21 Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Aliment Pharmacol Ther 2009 0.97
22 Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001 0.97
23 Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999 0.94
24 Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol 2006 0.93
25 Transjugular intrahepatic portosystemic shunts (TIPS): a decade later. J Clin Gastroenterol 2000 0.92
26 Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat 2011 0.91
27 Patent ductus venosus in an adult presenting as pulmonary hypertension, right-sided heart failure, and portosystemic encephalopathy. Am J Med 2001 0.87
28 Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther 2014 0.84
29 Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. J Viral Hepat 2010 0.84
30 Health-related quality of life (HRQL) in chronic liver disease. Dig Liver Dis 2005 0.84
31 Hepatitis C virus RNA assays: a comparison of SuperQuant and Monitor. J Clin Gastroenterol 2001 0.83
32 Survival and resource utilization in liver transplant recipients: the impact of admission to the intensive care unit. Transplant Proc 2003 0.82
33 Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis 2015 0.82
34 The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med 2000 0.81
35 The metabolic syndrome and nonalcoholic fatty liver disease. Panminerva Med 2006 0.81
36 Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations. Clin Exp Rheumatol 2004 0.80
37 Chronic liver disease and health-related quality of life. Gastroenterology 2001 0.78
38 Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). J Viral Hepat 2011 0.78
39 Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations. Am J Gastroenterol 2001 0.78
40 Mortality associated with alcohol-related liver disease. Aliment Pharmacol Ther 2013 0.78
41 Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2001 0.77
42 Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply. Aliment Pharmacol Ther 2014 0.75
43 Viral hepatitis guide for practicing physicians. Cleveland Clinic of Medicine. Cleve Clin J Med 2000 0.75
44 In diagnosing hepatitis C, which patient needs which test? Cleve Clin J Med 1999 0.75
45 Symptomatic porphyria cutanea tarda and B-immunoblastic lymphoma: is there an association? Am J Hematol 1996 0.75
46 Treatment of Crigler-Najjar type II with small-dose phenobarbital. Dig Dis Sci 1995 0.75